An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne

Phase 3

Completed

Interventions: Other: Adapalene gel with Eucerin
Other: Adapalene gel
Other: Adapalene gel with placebo moisturizer

Brief Summary: Acne is an inflammation of sebaceous glands and follicles. Applying topical treatments such as adapalene gel may cause irritant adverse effects. Hence, using a moisturizer is another way to protect or relieve this undesirable event. Moisturizers that have anti-inflammatory property could reduce irritant effects, emergent from using topical treatment and also reduce severity of acne.

Research teams chose an adapalene gel to act as topical treatment for curing acne. It has anti-inflammatory and comedolytic effects and has fewer side effects than other groups of topical retinoic acids. However, peeling skin, redness skin, tingling sensation or itching sensation may occur if they are continually used for a long period. Thus, for the purpose of studying the efficacy of moisturizer containing licochalcone A, L-carnitine and 1,2-decanediol in reducing irritant effect of using adapalene gel (Licochalcone A has anti-inflammatory effect, L-carnitine decrease sebum production and 1,2-decanediol has anti-bacterial effect).

Detailed Description: The investigators team research with patients by separate patients into 3 groups and compare among each other. In the first group use only adapalene gel, the second group use adapalene gel with moisturizer containing three substances mentioned above, and the last group use adapalene gel with placebo moisturizer. To compare outcomes among 3 groups, the investigators will measure degree of redness, scale, oily face, moist, number of acne, quality of life, and satisfaction after using moisturizer.

Recruitment & Eligibility

Inclusion Criteria

Age 18 years old or above
Participants have to control the birth for example, condom method, intrauterine device method before participate in the research at least 1 month until 6 months after research finish.
being diagnosed acne vulgaris by dermatologist in mild to moderate degree based on Investigators' Global Assessment scale of FDA

Exclusion Criteria

Use oral or injected antibiotics or other oral medicine treating acne for example, isotretinoin, oral contraceptives, or spironolactone group during 4 weeks before participate this research
Have other active skin diseases at face during 2 weeks before participate the research
Allergic to adapalene gel and moisturizer
Have severe or uncontrolled underlying diseases
Getting pregnant or during breast feeding
Other types of acne(not acne vulgaris)

Arm && Interventions

Group	Intervention	Description
Adapalene gel with Eucerin	Adapalene gel with Eucerin	Morning * Wash face by prepared facial foam and dry their face * Apply Eucerin cream all over the face Evening * Wash face by prepared facial foam and dry your face * Apply adapalene gel all over the face * Apply Eucerin cream all over the face
Adapalene gel	Adapalene gel	Evening * Wash face by prepared facial foam and dry your face * Apply adapalene gel all over the face
Adapalene gel with placebo moisturizer	Adapalene gel with placebo moisturizer	Morning * Wash face by prepared facial foam and dry their face * Apply placebo cream all over the face Evening * Wash face by prepared facial foam and dry your face * Apply adapalene gel all over the face * Apply placebo cream all over the face

Primary Outcome Measures

Name	Time	Method
Skin Tolerability: Transepidermal Water Loss (TEWL)	Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.	Skin tolerability was assessed by measuring TEWL with the Tewameter TM300
Skin Tolerability: Skin Sebum Content and Skin Hydration	Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.	Skin tolerability was assessed by measuring the skin surface sebum content, skin hydration with the Sebumeter SM815 and Corneometer CM825, respectively
Reduction of Undesirable Effects	2nd week, 4th week, and 8th week	* Undesirable effects were evaluated from skin's condition/signs(erythema, dryness and scaling) are evaluated by dermatologist. (none; mild; moderate; severe) and subject interview/symptoms(stinging/burning and pruritis) are evaluated by participants.(none; mild; moderate; severe). There were assessed at 2nd week, 4th week, and 8th week. * The worst score of each parameter which was defined as the worst local tolerance score is demonstrated and compared among 3 groups as shown.

Secondary Outcome Measures

Name	Time	Method
Reduction of Severity of Acne	baseline, 2nd week, 4th week and 8th week	* Evaluation from mean counts of inflammatory, noninflammatory, and total acne lesions at baseline, and at 2, 4, and 8 weeks * Total acne lesions = inflammatory + noninflammatory acne lesions * Reduction of lesions counts are considered to be a better outcome
Reduction of Severity of Acne: Acne Severity Index (ASI)	baseline, 2nd week, 4th week and 8th week	* The ASI score was calculated from the number of papules + (2 x pustules) + (comedones/4) * Decrease of ASI score are considered to be a better outcome